Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Total Liabilities (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Total Liabilities for 13 consecutive years, with $741.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 3.01% year-over-year to $741.7 million, compared with a TTM value of $741.7 million through Sep 2025, up 3.01%, and an annual FY2024 reading of $704.6 million, up 10.26% over the prior year.
  • Total Liabilities was $741.7 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $742.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $766.9 million in Q1 2025 and bottomed at $440.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $621.1 million, with a median of $625.7 million recorded in 2022.
  • The sharpest move saw Total Liabilities surged 223.8% in 2021, then increased 0.03% in 2023.
  • Year by year, Total Liabilities stood at $472.0 million in 2021, then rose by 29.83% to $612.8 million in 2022, then rose by 4.27% to $639.0 million in 2023, then grew by 10.26% to $704.6 million in 2024, then rose by 5.27% to $741.7 million in 2025.
  • Business Quant data shows Total Liabilities for TNDM at $741.7 million in Q3 2025, $742.5 million in Q2 2025, and $766.9 million in Q1 2025.